Ignite Creation Date:
2025-12-24 @ 10:58 PM
Ignite Modification Date:
2026-01-04 @ 2:15 AM
Study NCT ID:
NCT05501769
Status:
COMPLETED
Last Update Posted:
2025-09-26
First Post:
2022-08-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
Sponsor:
Arvinas Estrogen Receptor, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-09-08
Start Date Type:
ACTUAL
Primary Completion Date:
2024-07-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-08-25
Completion Date Type:
ACTUAL
First Submit Date:
2022-08-09
First Submit QC Date:
None
Study First Post Date:
2022-08-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-23
Last Update Post Date:
2025-09-26
Last Update Post Date Type:
ESTIMATED